Skip to main content
. 2022 Feb 7;106(4):1215–1226. doi: 10.4269/ajtmh.21-0942

Figure 4.

Figure 4.

Antibodies to Plasmodium falciparum circumporozoite protein (PfCSP) by ELISA 2 weeks after the final vaccine dose (A) and immediately prior to controlled human malaria infection (CHMI) (6–7 weeks after the final vaccine dose) (B). For each group results are paired by subjects who were not infected (•) or infected (^) after CHMI.